Immunotherapy with chimeric antigen receptor (CAR) T cells has emerged as a promising modality of treatment for patients with relapsed or refractory (R/R) malignancy. CAR T cells are patient-derived T cells that are genetically modified ex vivo, using a retroviral vector, to specifically target cancer antigens on the surface of malignant cells.
- It's All GREEK To Me! The NEPENTHE Trial for Relapsed/Refractory Neuroblastoma; Personalized Molecularly Targeted Treatment (200)
- A Sustainable Community Engagement Program Model to Address Hematopoietic Cell Transplantation Education Needs for Patients with Sickle Cell Disease (201)
- Beyond Pain Crises: Acute Complications of Sickle Cell Disease (202)
- The First 6 months: Health Care in the United States under a new President (213)
- Central Line-Associated Bloodstream Infections in Pediatric Hem/Onc/BMT Patients: An Update and Appraisal of the Evidence (203)